Apigenin Suppresses Cancer Cell Growth through ERβ  by Mak, Paul et al.
Apigenin Suppresses Cancer Cell Growth through ERB1
Paul Mak*, Yuet-Kin Leung y, Wan-Yee Tang y, Charlotte Harwood* and Shuk-Mei Ho y
*Department of Surgery, University of Massachusetts Medical School, Worcester, MA 01605, USA; yDepartment of
Environmental Health, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
Abstract
Two flavonoids, genistein and apigenin, have been
implicated as chemopreventive agents against prostate
and breast cancers. However, the mechanisms behind
their respective cancer-protective effects may vary
significantly. The goal of this study was to determine
whether the antiproliferative action of these flavonoids
on prostate (DU-145) and breast (MDA-MB-231) cancer
cells expressing only estrogen receptor (ER) B is
mediated by this ER subtype. It was found that both
genistein and apigenin, although not 17B-estradiol, ex-
hibited antiproliferative effects and proapoptotic ac-
tivities through caspase-3 activation in these two cell
lines. In yeast transcription assays, both flavonoids
displayed high specificity toward ERB transactivation,
particularly at lower concentrations. However, in mam-
malian assay, apigenin was found to be more ERB-
selective than genistein, which has equal potency in
inducing transactivation through ERA and ERB. Small
interfering RNA-mediated downregulation of ERB ab-
rogated the antiproliferative effect of apigenin in both
cancer cells but did not reverse that of genistein. Our
data unveil, for the first time, that the anticancer action
of apigenin is mediated, in part, by ERB. The differential
use of ERA and ERB signaling for transaction between
genistein and apigenin demonstrates the complexity
of phytoestrogen action in the context of their anti-
cancer properties.
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Introduction
Flavonoids present in soy, fruits, and vegetables have been
implicated as chemopreventive agents for a variety of
cancers [1–3]. The best-studied flavonoid is genistein, an
isoflavone abundant in soy. The beneficial effects of dietary
soy are supported by epidemiological observations that
countries with high soy consumption, such as China and
Japan, have lower incidences of prostate and breast
cancers than countries with little or no soy consumption
[4]. In experimental models, dietary genistein reduces the
incidence of prostate [5] and breast cancers [6,7]. Cellular
and molecular mechanisms underpinning the anticancer
effects of genistein cover a broad array of cellular processes,
including suppression of cell growth, angiogenesis, oxidative
stress, and tissue responses to estrogens [8]. Genistein is also
recognized as a phytoestrogen because it binds to estrogen
receptors (ERs) and exhibits both weak estrogenic and anti-
estrogenic activities.
Recently, the antitumor action of another dietary flavonoid,
apigenin (4V,5,7-trihydroxyflavone), has received growing at-
tention. It is abundantly present in leafy plants and vegetables
(e.g., parsley, artichoke, basil, and celery) [9], but its production
from manufacturers comes from extracts of dried flower heads
ofMatricaria chamomilla L. (http://ntp.niehs.nih.gov/ntp/htdocs/
Chem_Background/ExSumPdf/Apigenin.pdf; accessed July 8,
2006). As a nutriceutic, apigenin is most widely used in treat-
ing anxiety and sleep disorders because it has been shown
to possess sedative, antispasmodic, and spasmolytic actions
[10]. The flavonoid also holds great promise as a chemopre-
ventive agent for a variety of cancers. It exhibits significant ac-
tivity against UV-induced DNA damage and thus may protect
against skin cancer [11,12]. It inhibits the growth of a variety of
human cancer cells, including leukemia and breast, colon,
skin, thyroid, and prostate cancers [13,14]. Reported mecha-
nisms associated with its antitumor action include induction
of cell cycle arrest and apoptosis through a tumor necrosis
factor– induced NFnB-mediated apoptosis pathway [14,15],
attenuation of the phosphorylation of epidermal growth factor
receptor and MAP kinase [16], promotion of HER-2/neu degra-
dation [17], and activation of the intrinsic apoptosis pathway
[18,19]. However, the likelihood that apigenin acts as an estro-
gen or antiestrogen has not been considered as a mechanism
mediating its antitumor action.
It is now known that the actions of estrogens, antiestrogens,
and phytoestrogens are mediated by two ER subtypes (ERa
and ERb) whose expression levels vary dramatically among
different organs or cell types [20]. The two receptors regu-
late different sets of biologic functions and incite dissimilar
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responses within the same cell type or tissue. Furthermore, it
has become apparent that the actions of these receptors
vary dramatically, depending on whether they exist alone or
together in a cell [21,22]. Because genistein and other
phytoestrogens have been shown to preferentially use ERbs
over ERas as signaling mediators [23–26], it is reasonable
to anticipate that apigenin exhibits a similar preference
for estrogenicity.
The present study seeks to test the hypothesis that
apigenin-induced cancer cell death is mediated by ERb and
neither by ERa nor androgen receptor. The prostate cancer
cell line DU-145 [27,28] and the breast cancer cell line MDA-
MB-231 [29,30] were chosen as study models because
they both express only ERb. The growth-inhibitory action of
apigenin on these cancer cell lines was examined in the pres-
ence or in the absence of small interfering RNA (siRNA)–
mediated downregulation of the receptor. The transactivation
activities of apigenin at the estrogen-responsive element
(ERE), through ERb, were compared to those mediated
by ERa. Comparisons were also made between apigenin,
17b-estradiol (E2), ICI-182,780 (ICI), and genistein to eluci-
date the estrogenic properties of apigenin.
Materials and Methods
Reagents and Chemicals
Yeast synthetic dropout media were obtained from Clon-
tech (Takara Bio, Palo Alto, CA). All steroids, phytoestrogens,
and etoposide used in this study were purchased from Sigma
(St. Louis, MO). The antiestrogen ICI was kindly supplied
by Zeneca Pharmaceuticals (Cheshire, UK). The Beta-Glo
Assay System was purchased from Promega (Madison, WI).
DNA restriction enzymes were obtained from New England
Biolabs, Inc. (Beverly, MA). Antibodies against human ERa
(sc-8005) or ERb (sc-8974) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA).
Cell Lines and Culture Conditions
Two human prostate cancer cell lines (DU-145 and PC-3),
a breast cell line (MDA-MB-231), and an embryonic kidney
cell line [human embryonic kidney (HEK) 293] were obtained
from American Type Culture Collection (Manassas, VA).
DU-145 and HEK293 cells were maintained in DMEM sup-
plemented with 10% heat-inactivated fetal calf serum,
nonessential amino acids, and penicillin/streptomycin (Invi-
trogen, Carlsbad, CA). PC-3 and MDA-MB-231 cells were
maintained in DMEM/F12 or MEM-a medium, respectively,
supplemented in the same fashion. Cells were maintained
at 37jC and 5% CO2.
Cell Viability Assay
Cell viability assays were conducted in phenol red–free
medium supplemented with 5% charcoal-stripped serum,
nonessential amino acids, and penicillin/streptomycin. Cells
were plated at 4  103 cells/well in 200 ml of phenol red–free
medium in 96-well plates. Stock solutions of compounds in
dimethyl sulfoxide (DMSO) were stored at 10 mM and mixed
with fresh medium to achieve a final concentration of 10 nM
E2, 1 mM ICI, or 20 mM genistein or apigenin. Cells were
allowed to adhere for 24 hours, at which time themediumwas
removed and replaced with media containing one of the
above agents. Control cultures received amedium containing
the vehicle DMSO. Treatment was performed in triplicate and
repeated at 48-hour intervals. On the sixth day, cell viability
was determined by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium;
inner salt] assay, as described previously [31]. The medium
was aspirated, and the cells were washed once with 200 ml of
Hanks balanced salt solution. Ten microliters of MTS reagent
(CellTiter 96 Aqueous One Solution Reagent; Promega) and
50 ml of medium were added to each well. Following 1 to
4 hours of incubation at 37jC and 5% CO2, absorbance was
recorded by mQuant microplate reader (Biotek, Winooski,
VT) at a wavelength of 490 nm.
Caspase-3 Assay
DU-145 or MDA-MB-231 cells were plated into six-well
plates at 3 105 cells/well in 3ml of phenol red–freemedium
and allowed to attach for 24 hours. Cells were treated with
10 nM E2, 1 mM ICI, and 20 mM etoposide, genistein, or
apigenin. Control cultures were treated with vehicle alone
(DMSO). Treatment time was 48 hours. The presence of
apoptotic cells was determined by measuring caspase-3
using the BD ApoAlert Colorimetric Caspase-3 assay (Clon-
tech), according to the manufacturer’s instructions.
Knockdown of ER by Specific siRNA
Culture conditions for DU-145 (ERa and ERb+) and
MDA-MB-231 (ERa and ERb+) have been described pre-
viously [27,29]. Cells were plated in 96-well or 6-well plates
for MTS assay or RNA extraction, respectively, 1 day before
transfection with siRNA oligonucleotides. Cells were trans-
fected with 50 nM siRNA oligonucleotide using Lipofect-
amine2000 (Invitrogen), according to the manufacturer’s
protocol. siRNA against ERb was purchased from Dharma-
con’s siGENOME SMART pool selection (Lafayette, CO)
and was proven to knock down ERb expression at the mRNA
level by at least 75%. Negative control siRNA, an siCON-
TROL pool, and transfection siRNA control (siTOX) were
included to ensure the specificity and transfection efficiency
of siRNA. Twenty-four hours after transfection, cells were
incubated with 10 or 20 mM apigenin or genistein for another
72 hours and subsequently analyzed for cytotoxicity with
MTS assay. To correct for nonspecific toxic effects of siRNA,
cell viability after treatments with a phytoestrogen (siESR2 +
phytoestrogen or siCTL + phytoestrogen) was normalized
against its respective no-phytoestrogen-treatment control
(siESR2 alone or siCTL alone).
Reverse Transcription–Polymerase Chain Reaction
(RT-PCR) Analysis of ER Transcript Levels
Total RNA was isolated from transfected cells with TRI
reagent (Sigma), according to the manufacturer’s protocol.
The integrity of RNA was confirmed by denaturing gel, as
described previously [32]. Total RNA (4 mg) from each sample
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was reverse-transcribed to cDNA by Superscript II reverse
transcriptase (Invitrogen). Semiquantitative RT-PCR was
performed using Platinum Taq polymerase (Invitrogen) with
ERb-specific primers [33]. The forward and reverse primers
for b-actin have been described previously [27].
Construction of Yeast Strains
The yeast expression (YEpE10) and reporter (YEp-vERE)
plasmids for ERa were kindly supplied by Dr. Tauseef Butt
(LifeSensor, Inc., Malvern, PA). These plasmids were used
to transform the protease-deficient yeast strain BJ2168 ac-
cording to standard protocol [34]. This double-transformant
yeast strain was grown in synthetic dropout medium (TRP
URA). The yeast strain expressing ERb in the presence of an
estrogen-responsive reporter plasmid (YEp-vERE) has re-
cently been described [33]. This double-transformant yeast
strain was grown in synthetic dropout medium (LEUURA).
Yeast-Based Transcription Assays
To study the hormone responsiveness of ERa or ERb,
double yeast transformants carrying an expression plasmid
for ERa or ERb and a reporter plasmid (YEp-vERE) were
selected for ligand-dependent transcriptional activity. Ex-
pression of ERb was analyzed by Western blot analysis [35]
using an N-terminal–specific H-150 polyclonal antibody
(Santa Cruz Biotechnology). Because CUP1 promoter was
moderately leaky in this experiment (data not shown), addi-
tion of copper was not necessary to induce ERb expression.
All selected transformants were grown in a synthetic dropout
medium in a 96-well plate overnight at 30jC, either in the
absence (control) or in the presence of steroids and phyto-
estrogens (0.01 nM–10 mM). A ligand-dependent trans-
activation assay was performed using the Beta-Glo Assay
System (Promega), according to themanufacturer’s protocol.
Induction of the reporter gene (luciferase activity in relative
light units) was measured by the Victor 2 system (Perkin
Elmer, Wellesley, MA).
Transactivation Activity of ERa and ER
in a Mammalian System
Mammalian expression vectors ERa and ERb were gifts
from Dr. Leigh C. Murphy (University of Manitoba, Winnipeg,
Canada) [36]. The luciferase reporter plasmid carrying 3X
vitellogenin ERE was kindly provided by Dr. Craig Jordan
(Fox Chase Cancer Center, Philadelphia, PA) [37].
HEK293 cells at a density of 1.5  104 ml1 were seeded
onto a 24-well plate. Regular culturemediumwas replaced by
phenol red–free DMEM with 5% charcoal-stripped serum.
The cells were allowed to adopt an estrogen-free envi-
ronment for 48 hours before transfection. Vectors expressing
ERa or ERb + ERE luciferase and b-galactosidase were
transfected into the cells using Lipofectamine Plus (Invitro-
gen). After 24 hours of transfection, E2 (100 pMand 1 nM), ICI
(10 nM and 1 mM), apigenin (100 nM and 1 mM), and genistein
(100 nM and 1 mM) were applied to the culture. In separate
experiments, cells were treated with E2, apigenin, or genis-
tein in the absence or in the presence of the antiestrogen ICI.
Luciferase reporter assay was performed as suggested in
the Bright Glo Luciferase assay kit (Promega) to determine
transactivation activity after 24 hours of treatment with hor-
mones/compounds. Activities of b-galactosidase were mea-
sured by a b-gal assay kit (Promega) to normalize the
transfection efficiency of each well.
Statistical Analysis
Data were expressed as mean ± SD. The statistical
significance of the difference in means among treatment
groups was determined with Systat software (Student ver-
sion 6.0.1; SPSS, Chicago, IL) for one-way ANOVA followed
by Tukey post hoc analyses. P < .05 was considered as a
statistically significant difference between the two groups.
Results
Apigenin and Genistein Suppressed Cell Growth through
Induction of Apoptosis in DU-145 and MDA-MB-231 Cells
The effects of E2 (10 nM), ICI (1 mM), genistein (20 mM), or
apigenin (20 mM) on the growth of DU-145 and MDA-MB-231
in charcoal-stripped medium were examined. At the doses
tested, E2 exerted no impact on the growth (Figure 1A and B)
or the apoptosis (Figure 1C and D) of either cell lines,
whereas ICI induced a small reduction in cell number and
an increase in caspase-3 activation in DU-145 cells when
compared with control vehicle (DMSO), but not in MDA-MB-
231 cells. On the contrary, apigenin and genistein effectively
suppressed the growth of both cell lines. Apigenin was more
effective than genistein in suppressing DU-145 cell growth
(Figure 1A) but exhibited potency equal to that of genistein
in inhibiting MDA-MB-231 proliferation (Figure 1B). The
growth inhibition induced by the two phytoestrogens paral-
leled their abilities to induce caspase-3 activation. Apigenin
and genistein were equally effective in causing caspase-3
activation in both cell lines (Figure 1C and D).
Differential Transcriptional Activation of ERa and ER in
Response to Estrogens and Phytoestrogens in Yeast Cells
The transcriptional activities of E2, ICI, genistein, and
apigenin through ERa and ERb were evaluated in a yeast
system. As expected, E2 was found to transactivate better
through ERa than through ERb (Figure 2A). Interestingly,
although ICI is a well-recognized antagonist in mammalian
cell studies, it behaved as an agonist in yeast cells, trans-
activatingmoreeffectivelywithERa thanwithERb (Figure 2B).
This finding is in agreement with findings in a previous re-
port using yeast reporter assays [38]. In contrast to E2 or ICI,
apigenin and genistein behaved as ERb-selective ligands at
low phytoestrogen concentrations. At higher ligand con-
centrations, they still elicited much higher transactivation ac-
tivities through ERb than through ERa (Figure 2C and D).
Differential Transactivation of ERa and ER in Response
to Estrogens and Phytoestrogens in Mammalian Cells
The HEK293 cell line was chosen as a mammalian
reporter assay system due to its low background as a tran-
scription assay and the absence of endogenous ERa and
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Figure 1. Effects of genistein or apigenin on the proliferation of (A) DU-145 and (B) MDA-MB-231 cells. Cells were treated with 10 nM E2, 1 M ICI, 20 M
genistein, or 20 M apigenin for 72 hours. Control (CTL) cultures were treated with solvent vehicle in a charcoal-stripped serum-supplemented medium. Cell
viability was determined by MTS assay, as described in the Materials and Methods section. (C and D). Induction of relative caspase-3 activity by genistein or
apigenin in (C) DU-145 and (D) MDA-MB-231 cells. Cells were treated with E2, ICI, genistein, and apigenin at the concentrations described above. E2 and
etoposide serve as negative and positive control, respectively, for this experiment. Caspase-3 activities are normalized with respect to the control vehicle (DMSO).
Twenty micromolars of etoposide was used as positive control. Data represent the averages (histograms) of three separate experiments, with the standard
deviation indicated. aStatistically significant difference between the treatment group and the control group (control vehicle for A and B; E2 for C and D) at P < .05.
Figure 2. Differential transcriptional activation of ERa and ER1 in yeast. Yeast strains harboring the expression vectors for ERa (red square) or ER1 (blue
triangle) and the vitellogenin ERE reporter plasmid were incubated with an increasing concentration of E2 (A), ICI (B), apigenin (C), or genistein (D). After 24 hours
of incubation at 30jC, Beta-Glo assays were performed. Luciferase activity (relative light units) was recorded by a luminometer (Victor 2 system). Each point
represents an average of triplicates with standard deviations.
Apigenin Triggers Apoptosis through ERB Mak et al. 899
Neoplasia . Vol. 8, No. 11, 2006
ERb expression [33]. When physiological concentrations of
E2 (100 pM and 1 nM) were used, this ligand elicited potent
dose-dependent transactivation responses through ERa
(Figure 3A). In contrast, E2 elicited only low levels of trans-
activation through the ERb. Contrary to results obtained in
yeast systems, the antiestrogen ICI was inactive in these
mammalian transcription assays regardless of its action
being mediated by ERa or ERb. In this regard, the results
are consistent with the widely accepted notion that ICI is an
estrogen antagonist for mammalian cells. The two phyto-
estrogens clearly exhibited agonistic actions in mammalian
reporter assays. Apigenin was a weak agonist at a lower
concentration (100 nM) compared to genistein, which
achieved maximal transactivation through ERa and ERb at
the same concentration. At a higher concentration (1 mM),
apigenin exhibited clear ERb selectivity; it induced signifi-
cantly higher transactivation through ERb than through
ERa. Thus, these data appear to corroborate those observed
in yeast-based transcription assays, except for those related
to ICI, which acts as an agonist in yeast assays. Importantly,
all transcriptional activation activities induced by E2, apige-
nin, and genistein through ERb could be attenuated effi-
ciently by the coincubation of cell cultures with 1 mM ICI,
indicating that they were mediated by ERb (Figure 3B).
Similar results were obtained when this experiment was
conducted with ERa expressing HEK293 (data not shown).
ER Plays a Role in Apigenin-Induced Cancer Cell
Growth Inhibition
The relative efficacy of siRNA against ERb (ERb siRNA),
negative control siRNA (siCONTROL pool), and transfection
siRNA control (siTOX) in knocking down ERb transcripts in
transfected cells was determined by RT-PCR. As shown
in Figure 4A, ERb transcripts were reduced by > 85% in
DU-145 and MDA-MB-231 cells, whereas the other siRNA
(siCONTROL pool and siTOX) did not affect the expression
of ERb transcripts when compared to cultures without siRNA
transfection (control cultures were treated with Lipofectamine
alone). Transfection efficiency in these experiments was
estimated as 70%.
Subsequently, DU-145 and MDA-MB-231 cells were ex-
amined for cell viability after treatment with phytoestrogens.
For both cell lines, apigenin (10 and 20 mM) induced a
dose-dependent reduction in cell growth (Figure 4B and C),
whereas genistein caused only cell growth inhibition at the
high dose (20 mM) (Figure 4D and E ). Importantly, the
antiproliferation effects of apigenin on DU-145 and MDA-
MB-231 were effectively abrogated by transfecting the cells
Figure 3. (A) Transcriptional activation of ERa and ER1 in mammalian cells. HEK293 cells were transfected with vectors expressing ERa (red bar) or ER1 (blue
bar), -galactosidase, and a vector carrying 3X ERE luciferase reporter using Lipofectamine Plus, as described in the Materials and Methods section. After
24 hours, cells were treated with E2, ICI, apigenin, genistein, or solvent vehicle (CTL) and subsequently analyzed for luciferase activity. Data represent three
separate experiments with standard deviations. aStatistical significance between the treated group and untreated controls at P < .01. bNo significant difference
between the two groups. (B) Effects of ICI on the ligand responsiveness of ER1 in HEK293 cells were seeded onto 24-well plates and transfected with ER1
expression vector, 3X ERE luciferase reporter, and -galactosidase expression plasmids, as described above. Cells were treated with solvent vehicle (CTL), E2,
genistein, or apigenin in the absence (black bar) or in the presence (white bar) of 1 M ICI and subsequently analyzed for luciferase activity. Data represent three
separate experiments with standard deviation.
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with ERb siRNA (Figure 4B and C), but not by transfection of
siCONTROL (Figure 4B and C), siTOX (data not shown), or
ERa siRNA (data not shown). In contrast, genistein-induced
cancer cell growth suppression was not reversed by ERb
siRNA transfection (Figure 4D and E ).
Discussion
The two flavonoids genistein and apigenin have been
studied extensively for their antitumorigenic activities in var-
ious cancers, including prostate and breast cancers [8,14,15,
39,40]. Although many different mechanisms of action have
been proposed [8,13,16–18,39–42], a connection between
the anticancer effects of these flavonoids and ERb has not
been described. Several reports have demonstrated that
interactions between ERa and ERb could significantly alter
the transactivation activities of each receptor and biologic
outcome [21,22]. Therefore, we have chosen the two cancer
cell lines DU-145 and MDA-MB-231, which express only
ERb [27,29], to compare the antiproliferative effects of two
flavonoids. Furthermore, because transcriptional activities
of a nuclear receptor could be markedly altered by post-
translational protein modification and coregulator interaction
in mammalian cells [43], we have evaluated the transcrip-
tional potentials of these two flavonoids in yeast and mam-
malian reporter assays. Because yeast cells are devoid of
transcription coregulators and most posttranslational protein
modification pathways, basal transcriptional activities could
be obtained for comparison with activities in a mammalian
reporter system (HEK293). In this study, we found that the
exposure of DU-145 or MDA-MB-231 cells to either flavo-
noid elicited suppression of cell growth and activation of
caspase-3—a hallmark of apoptosis. In regard to the con-
centrations of genistein or apigenin used and the extent of
growth inhibition/apoptosis induction in cancer cells, our
findings were consistent with those reported by others
[8,19,39,44–46]. For example, genistein has been reported
to trigger apoptosis in breast cancer through calcium-
dependent and calpain/caspase-12–dependent pathways
[47]. In both yeast and mammalian reporter assays, the two
flavonoids were found to act as agonists at the ERE and to
exhibit ERb selectivity for transactivation when compared to
E2, which transactivates most effectively through the ERa.
Between the two flavonoids, apigenin was found to be more
selective with transactivations by ERb than was genistein,
which was equally potent in eliciting transactivation through
Figure 4. (A) ER1 knockdown experiments in DU-145 and MDA-MB-231 cells. Cells were transfected with 50 nM siRNA against ER1 or scrambled siRNA
(siCONTROL), as described in the Materials and Methods section. After 72 hours of incubation, total RNA was extracted and semiquantitative RT-PCR was
performed using specific primers against ER1 and -actin. Similar results were obtained from two separate experiments. (B–E) Antiproliferation effects of
apigenin or genistein on ER1 knockdown DU-145 and MDA-MB-231 cells. siRNA against ER (siESR2)– and siRNA scrambled control (siCONTROL)–
transfected cells were incubated with 10 or 20 M apigenin (B and C) or genistein (D and E) for 72 hours and subsequently analyzed for cytotoxicity by MTS assay,
as described in the Materials and Methods section. Control groups (Lipofectamine2000) without siRNA transfection were treated with vehicle (CTL). The viability of
the cells with apigenin or genistein treatment (siESR2 + phytoestrogen or siCTL + phytoestrogen) was normalized to values obtained in cultures treated similarly
but without phytoestrogens (siESR2 alone and siCTL alone). The cell viability in each treatment group was calculated as a percentage of the value found in
untreated controls without siRNA transfection. Data represent the average of three separate experiments, with standard deviation indicated. aThe mean of the
treated group was statistically different from that of untreated controls at P < .05. bNo significant difference between the treated group and the untreated control.
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the two ER subtypes. The major contribution of our study,
however, resides in the finding that the antiproliferative/
proapoptotic effect of apigenin is apparently mediated by
ERb, whereas that of genistein, at least in these two cell
models, does not involve the receptor. To the best of our
knowledge, this study, which used siRNA knockdown of ERb,
is the first to demonstrate the involvement of this ER subtype
in the antiproliferative/proapoptotic effect of apigenin.
In DU-145 cell cultures, apigenin-induced growth inhibi-
tion was noticeably greater than that induced by genistein,
whereas in MDA-MB-231 cell cultures, both flavonoids
exhibited comparable potency. Consistent with our previous
observations, E2 was found to exert little effect on the growth
of DU-145 cells, whereas ICI induced a modest inhibitory
action [27]. The action of the antiestrogen on the prostate
cancer cell line was shown to be dependent on ERb [27] and
may involve a crosstalk with theNFnB signaling pathway [48].
Morrissey et al. [18] suggested that apigenin-mediated apop-
tosis in DU-145 may not involve ERs. Their conclusion was
reached based on the cotreatment of apigenin-exposed
DU-145 cells with ICI and their observation of a lack of
attenuation of the apigenin effect. Our findings offer a pos-
sible explanation for their observation. Because ICI could
exhibit its antiproliferative/proapoptotic on DU-145 cells per
se [27], the addition of ICI to apigenin-treated cells would
unlikely block the proapoptotic effects of apigenin. In this
study, our use of siRNA to specifically knock down ERb
proves to be a better approach to demonstrating the involve-
ment of the receptor in apigenin action.
In MDA-MB-231 breast cancer cells, as expected [49], E2
did not stimulate cell growth and ICI had no action on
proliferation/apoptosis. These findings are consistent with
previously reported findings that the lack of ERa in this cell
line makes it insensitive to estrogen stimulation in terms of
cell proliferation. In contrast, both genistein and apigenin are
effective antiproliferative/proapoptotic agents for this ERa
cell line. In the case of apigenin, its action was found to be
mediated by ERb in this study. If our observation in MDA-
MB-231 could be extended to ERa breast cancers, apigenin
might have clinical utility in the chemoprevention of the
recurrence of these cancers [50].
In the present study, we demonstrated that apigenin and
genistein, when compared to E2, exhibit markedly differ-
ent transactivation potencies through the two ER subtypes.
E2 effectively induces ERa-mediated transcription but only
triggers minimal transactivation through ERb. In contrast,
apigenin and genistein are excellent ERb-mediated trans-
activators. This property of the two flavonoids is most notice-
able in yeast reporter assays, which lack modulations from
endogenous transcriptional coregulators or cofactors. Even
in mammalian cell assays (HEK293 cells), both flavonoids
are highly effective in eliciting ERb-mediated transactivation.
A key difference between the two resides in the strong
selectivity of apigenin for ERb-mediated transactivation,
whereas genistein is equally effective in activating ERa-
mediated and ERb-mediated transcription. Collectively, find-
ings from yeast andmammalian reporter assays suggest that
apigenin is an ERb-selective ligand, whereas genistein can
activate both receptor subtypes. This conclusion is corrobo-
rated by a recent report that found genistein to have a higher
binding affinity toward ERa than does apigenin [51].
The differences between these two flavonoids as phytoes-
trogens could be related to several key attributes that define
the mode of estrogen action. Generally speaking, phyto-
estrogens have weak binding affinities for both ER subtypes,
but they bind ERb better than ERa [52]. However, a greater
binding affinity of a phytoestrogen for a specific ER subtype
does not always correlate with its ability to better transacti-
vate gene expression through that receptor [53,54]. Other
important factors that determine selectivity for an ER subtype
include the ability of the phytoestrogen to create a high-
affinity coregulator-binding pocket by the correct positioning
of helix 12 within the ligand-binding domain of the ER–ligand
complex [55]. In this regard, phytoestrogens have been
shown to confer ERb with coregulator-recruiting affinity
higher than that of ERa [23,56]. Although most soy iso-
flavones, including genistein, are believed to exert their ac-
tions primarily through ERb signaling [57,58], recent studies
[59,60] have raised doubts about this assumption. Our data
from HEK293 reporter assays support these doubts as
genistein was found to be equally effective in eliciting trans-
activation through either ER subtype. This lack of selectivity
of genistein for ERb signaling may pose a limit to its use as a
chemopreventive agent for breast cancer because its ERa
activity may post concern for increasing the risk of recurrence
of ERa breast cancers, undesirable uterotrophic activities,
and thromboembolic disorders. It is well established that
estrogen action on the uterus and liver is exclusively me-
diated by ERa signaling [61].
The most intriguing finding of the current study is that the
siRNA-mediated knockdown of ERb blocked only the growth-
inhibitory effect of apigenin—not that of genistein—on
DU-145 and MDA-MB-231 cells. This finding suggests that
the anticancer growth effect of apigenin—but not of genis-
tein—involves ERb. Indeed, pharmacological dosages
of genistein have been shown to trigger cytotoxic activities
through ER-independent pathways, such as inhibition of
tyrosine kinase and topoisomerase [62]. Although apigenin
has been shown to elicit pleiotropic effects on a variety of
pathways that mediate antitumor actions [14–17,19], our re-
port is the first one to associate it with ERb signaling. More
recently, genistein and apigenin have been demonstrated to
act as estrogen agonists in ERa/bMCF-7 and T47-D cells by
acting through ERa [29]. Whether apigenin could suppress
cell growth in other ER+ cancer cell lines remains to be de-
termined as both DU-145 and MDA-MB-231 cell lines ex-
press only ERb but not ERa [27–29]. It has been reported
that ERa can heterodimerize with ERb and alter its trans-
activation activity [21,22]. It is therefore logical to expect
cancer cells that express both ER subtypes to respond to
apigenin in a manner different from what has been demon-
strated in DU-145 and MDA-MB-231 cells. It is surprising
to find that the genistein-induced anticancer cell growth
action in DU-145 and MDA-MB-231 cells was not affected
by siRNA-induced downregulation of ERb. Although the anti-
cancer action of genistein on prostate and breast cancers
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has been widely reported, it remains uncertain whether it is
mediated through ERb. In this study, we showed that, at least
in two cancer cell lines that express only ERb, the anticancer
effects of genistein are mediated through mechanisms not
involving this receptor.
In summary, we have demonstrated the preferred usage
of ERb by apigenin as a mediator in suppressing the growth
of DU-145 and MDA-MB-231 cells. Overall, apigenin, when
compared to genistein, has a much stronger selectivity for
ERb than for ERa. Continued efforts placed on this area of
research might provide important insights on the synthesis
of highly selective ERb agonists for anticancer intervention.
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